Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Target Price
The average target price of ADVM is 5.0 and suggests 15% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas